Tourmaline Bio Basic EPS 2020-2025 | TRML

Tourmaline Bio basic eps from 2020 to 2025. Basic eps can be defined as a company's net earnings or losses attributable to common shareholders per basic share basis.

Tourmaline Bio Basic EPS 2020-2025 | TRML

Tourmaline Bio basic eps from 2020 to 2025. Basic eps can be defined as a company's net earnings or losses attributable to common shareholders per basic share basis.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$68.4B
Zoetis (ZTS)$67.8B
Takeda Pharmaceutical (TAK)$47.1B
Daiichi Sankyo, - (DSNKY)$46.2B
BeOne Medicines - (ONC)$33.9B
Sandoz Group AG (SDZNY)$25.8B
Summit Therapeutics (SMMT)$19.6B
Merck (MKKGY)$16.7B
Shionogi (SGIOY)$15.1B
United Therapeutics (UTHR)$14.1B
Neurocrine Biosciences (NBIX)$13B
Orion OYJ (ORINY)$10.8B
IPSEN (IPSEY)$10.6B
Madrigal Pharmaceuticals (MDGL)$8.2B
Corcept Therapeutics (CORT)$7.6B
Grifols, S.A (GRFS)$7.4B
Ionis Pharmaceuticals (IONS)$6.8B
Stevanato Group S.p.A (STVN)$6.7B
Hikma Pharmaceuticals Plc (HKMPF)$5.3B
Ono Pharmaceutical (OPHLF)$5.1B
Soleno Therapeutics (SLNO)$4.1B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.9B
NewAmsterdam Pharma (NAMS)$2.8B
Crinetics Pharmaceuticals (CRNX)$2.8B
Hypermarcas (HYPMY)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.5B
Centessa Pharmaceuticals (CNTA)$2.4B
Ocular Therapeutix (OCUL)$2.2B
Endo (NDOI)$1.8B
Dyne Therapeutics (DYN)$1.8B